These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 23466576)

  • 41. Reproducibility and genital sparing with a vaginal dilator used for female anal cancer patients.
    Briere TM; Crane CH; Beddar S; Bhosale P; Mok H; Delclos ME; Krishnan S; Das P
    Radiother Oncol; 2012 Aug; 104(2):161-6. PubMed ID: 22841019
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intensity modulated radiotherapy in anal canal squamous cell carcinoma: Implementation and outcomes.
    Das A; Arunsingh M; Bhattacharyya T; Prasath SS; Balakrishnan A; Mallick I
    J Cancer Res Ther; 2021; 17(4):975-981. PubMed ID: 34528551
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Toxicity and survival of anal cancer patients treated with intensity-modulated radiation therapy.
    Ghareeb A; Paramasevon K; Mokool P; van der Voet H; Jha M
    Ann R Coll Surg Engl; 2019 Mar; 101(3):168-175. PubMed ID: 30482037
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cervical lymph node metastases from unknown primary cancer: a single-institution experience with intensity-modulated radiotherapy.
    Villeneuve H; Després P; Fortin B; Filion E; Donath D; Soulières D; Guertin L; Ayad T; Christopoulos A; Nguyen-Tan PF
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1866-71. PubMed ID: 21497452
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma--the University of Iowa experience.
    Yao M; Dornfeld KJ; Buatti JM; Skwarchuk M; Tan H; Nguyen T; Wacha J; Bayouth JE; Funk GF; Smith RB; Graham SM; Chang K; Hoffman HT
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):410-21. PubMed ID: 16168834
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution.
    Holliday EB; Morris VK; Johnson B; Eng C; Ludmir EB; Das P; Minsky BD; Taniguchi C; Smith GL; Koay EJ; Koong AC; Delclos ME; Skibber JM; Rodriguez-Bigas MA; You YN; Bednarski BK; Tillman MM; Chang GJ; Jennings K; Messick CA
    Oncologist; 2022 Feb; 27(1):40-47. PubMed ID: 35305097
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prediction of acute toxicity grade ≥ 3 in patients with locally advanced non-small-cell lung cancer receiving intensity modulated radiotherapy and concurrent low-dose Cisplatin.
    Uyterlinde W; Belderbos J; Baas C; van Werkhoven E; Knegjens J; Baas P; Smit A; Rikers C; van den Heuvel M
    Clin Lung Cancer; 2013 Sep; 14(5):541-8. PubMed ID: 23835165
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evolution and Management of Treatment-Related Toxicity in Anal Cancer.
    Ludmir EB; Kachnic LA; Czito BG
    Surg Oncol Clin N Am; 2017 Jan; 26(1):91-113. PubMed ID: 27889040
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome.
    Milano MT; Jani AB; Farrey KJ; Rash C; Heimann R; Chmura SJ
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):354-61. PubMed ID: 16168830
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Early-stage Node-negative (T1-T2N0) Anal Cancer Treated with Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy.
    Franco P; Arcadipane F; Ragona R; Mistrangelo M; Cassoni P; Rondi N; Morino M; Racca P; Ricardi U
    Anticancer Res; 2016 Apr; 36(4):1943-8. PubMed ID: 27069184
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of oral cavity squamous cell carcinoma with adjuvant or definitive intensity-modulated radiation therapy.
    Sher DJ; Thotakura V; Balboni TA; Norris CM; Haddad RI; Posner MR; Lorch J; Goguen LA; Annino DJ; Tishler RB
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e215-22. PubMed ID: 21531515
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment outcomes and HPV characteristics for an institutional cohort of patients with anal cancer receiving concurrent chemotherapy and intensity-modulated radiation therapy.
    Foster CC; Lee AY; Furtado LV; Hart J; Alpert L; Xiao SY; Hyman NH; Sharma MR; Liauw SL
    PLoS One; 2018; 13(3):e0194234. PubMed ID: 29522569
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predictors of Radiation Therapy-Related Gastrointestinal Toxicity From Anal Cancer Dose-Painted Intensity Modulated Radiation Therapy: Secondary Analysis of NRG Oncology RTOG 0529.
    Olsen JR; Moughan J; Myerson R; Abitbol A; Doncals DE; Johnson D; Schefter TE; Chen Y; Fisher B; Michalski J; Narayan S; Chang A; Crane CH; Kachnic L
    Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):400-408. PubMed ID: 28463160
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Squamous cell carcinoma of the anal canal.
    Mitchell SE; Mendenhall WM; Zlotecki RA; Carroll RR
    Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):1007-13. PubMed ID: 11240241
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dose escalation in chemoradiation for anal cancer: preliminary results of RTOG 92-08.
    John M; Pajak T; Flam M; Hoffman J; Markoe A; Wolkov H; Paris K
    Cancer J Sci Am; 1996; 2(4):205-11. PubMed ID: 9166533
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combined modality therapy for HIV-infected patients with squamous cell carcinoma of the anus: outcomes and toxicities.
    Edelman S; Johnstone PA
    Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):206-11. PubMed ID: 16904522
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Capecitabine With Mitomycin Reduces Acute Hematologic Toxicity and Treatment Delays in Patients Undergoing Definitive Chemoradiation Using Intensity Modulated Radiation Therapy for Anal Cancer.
    Goodman KA; Julie D; Cercek A; Cambridge L; Woo KM; Zhang Z; Wu AJ; Reidy DL; Segal NH; Stadler ZK; Saltz LB
    Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1087-1095. PubMed ID: 28721892
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intensity-modulated Radiotherapy for Anal Cancer: Dose-Volume Relationship of Acute Gastrointestinal Toxicity and Disease Outcomes.
    Ng M; Ho H; Skelton J; Guerrieri M; Guiney M; Chao M; Blakey D; Macleod C; Amor H; Subramanian B; Melven L
    Clin Oncol (R Coll Radiol); 2018 Oct; 30(10):634-641. PubMed ID: 30049649
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Definitive chemoradiotherapy for anal canal cancer: single-center experience.
    Tachibana I; Nishimura Y; Inada M; Fukuda K; Ishikawa K; Nishikawa T; Yokokawa M; Nakamatsu K; Kanamori S; Hida JI
    Int J Clin Oncol; 2018 Dec; 23(6):1121-1126. PubMed ID: 29992389
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial.
    Arbea L; Martínez-Monge R; Díaz-González JA; Moreno M; Rodríguez J; Hernández JL; Sola JJ; Ramos LI; Subtil JC; Nuñez J; Chopitea A; Cambeiro M; Gaztañaga M; García-Foncillas J; Aristu J
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):587-93. PubMed ID: 22079731
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.